Dietary Fat Intervention Fails To Reduce Breast Cancer-related Deaths

Share this content:
Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.
Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death.

Dietary fat interventions in healthy postmenopausal women do not appear to lower the risk of breast cancer death, but among women who become breast cancer survivors, an intervention might reduce the risk of death, according to updated findings presented at the 2016 San Antonio Breast Cancer Symposium.1

“Compared to a usual-diet control group, women randomized to a low-fat dietary pattern had a non-significantly reduced risk of death from breast cancer and a significantly reduced risk of death after breast cancer,” said Rowan T. Chlebowski, MD, PhD, of the Los Angeles Biomedical Research Institute in California.

Across countries, age-adjusted death rates correlate linearly with total dietary fat intake, he noted.

The Women's Health Initiative Dietary Modification primary breast cancer prevention trial (ClinicalTrials.gov Identifier: NCT00000611) randomly assigned 48,835 postmenopausal women age 50 to 79 years, with no prior history of breast cancer and normal mammograms, to undergo dietary intervention (19,541 women) or to a control/comparison group (29,294). The dietary intervention reduced dietary fat intake to 20% of calories from fat, increased fruit and vegetable intake (5 servings a day), and increased grains to 6 servings a day.

Weight loss was not a study goal. During year 1, intervention group members participated in 18 group sessions and then quarterly “maintenance” meetings. The control group participants received dietary guidelines. Baseline characteristics were well-balanced between the 2 study groups.

Overall, the percentage of calories from dietary fat declined by 13.9% in year 1 and 8.2% by year 5, Dr Chlebowski said.

By year 4, the breast cancer incidence curves between members of the control and dietary-intervention groups began to separate. During a median of 8.5 years of dietary intervention, the difference in breast cancer incidence failed to achieve statistical significance. The groups saw 53 and 27 breast cancer deaths (hazard ratio [HR], 0.77; 95% CI: 0.48-1.22).

While deaths from breast cancer were not significantly associated with dietary intervention, by the 8.5-year mark, deaths after breast cancer were (HR, 0.65; 95% CI: 0.45-0.94; P = 0.02), Dr Chlebowski noted. At the 16-year mark, deaths after breast cancer were still lower than those in the control group (234 deaths versus 443; HR, 0.82; 95% CI: 0.70-0.96; P = 0.01).

RELATED: BRCA Mutations Associated With Carboplatin Outcomes in Triple-negative Breast Cancer

Subgroup analysis for deaths after breast cancer showed that the dietary intervention effect was stronger for women with a baseline waist circumference of 88cm or larger and with higher baseline levels of dietary fat intake.

“Future studies of other lifestyle interventions in breast cancer settings could consider some form of a low-fat dietary pattern as a base,” Dr Chlebowski concluded.

Reference

  1. Chlebowski RT, Aragaki AK, Thomson CA, et al. Low-fat dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial. Paper presented at: 39th San Antonio Breast Cancer Symposium; Dec 2016; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs